 we report financial results for the fourth quarter and year ended on march 7, 2016. 
 we also provide an update on our commercial activities including the status of the clinical studies of both ARX-04 and Zalviso.    
 # 1_#1 _ # 1_#1 _ =    # 1 1.25 in.125 in.25 in 